Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free GNCA Stock Alerts

Genocea Biosciences (GNCA) Competitors

Genocea Biosciences logo
Compare

GNCA vs. ARDS, CLVR, SMFL, VRPX, and NAVB

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Aridis Pharmaceuticals (ARDS), Clever Leaves (CLVR), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.09N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Genocea Biosciences Neutral

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Genocea Biosciences Neutral

Clever Leaves has higher revenue and earnings than Genocea Biosciences. Clever Leaves is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Clever Leaves' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Clever Leaves beats Genocea Biosciences on 7 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Smart for Life?

Genocea Biosciences (NASDAQ:GNCA) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.06, suggesting that its share price is 1,406% more volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Smart for Life Neutral

Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Smart for Life N/A N/A N/A

Smart for Life has higher revenue and earnings than Genocea Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Genocea Biosciences Neutral

Virpax Pharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Virpax Pharmaceuticals has a beta of -16.52, indicating that its stock price is 1,752% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Genocea Biosciences' return on equity of -182.88% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Genocea Biosciences N/A -182.88%-62.76%

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genocea Biosciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Genocea Biosciences (NASDAQ:GNCA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Navidea Biopharmaceuticals N/A N/A N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

GNCA vs. The Competition

Export
MetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6K$353.08M$7.16B$12.48B
Dividend YieldN/AN/A2.66%6.52%
P/E Ratio0.00N/A28.0224.70
Price / SalesN/A228.84540.3799.46
Price / CashN/A22.4449.2657.09
Price / BookN/A4.8610.966.46
Net Income-$33.20M-$141.03M$3.57B$337.01M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
ARDS
Aridis Pharmaceuticals
N/A$0.00
-86.7%		N/AN/A$21KN/A0.0030
CLVR
Clever Leaves
N/AN/AN/AN/A$18K$17.42MN/A560
SMFL
Smart for Life
N/A$0.00
flat		N/AN/A$14K$11.11MN/A110
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/A-97.1%$14KN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCA) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel